Macular degeneration is classified as either dry AMD or Wet AMD. The latter is less common and currently there is no cure for Age-related Macular Degeneration (AMD). AMD has been estimated to cost the UK at least £1.6bn a year. Around 600,000 people in the UK currently have sight loss caused by AMD and by 2050 that number will more than double to 1.3m.
We are investigating the development of a repurposed compound to see whether a treatment can be developed to alleviate AMD.